Early Real-Life Experience with Spesolimab in the Treatment of Generalized Pustular Psoriasis: A Case Series of Three Patients Treated in a Compassionate Use Program

TY - JOUR

T1 - Early Real-Life Experience with Spesolimab in the Treatment of Generalized Pustular Psoriasis

T2 - A Case Series of Three Patients Treated in a Compassionate Use Program

AU - Rittig, Anne Hald

AU - Bertelsen, Trine

AU - Stave, Sascha Dinsen Wreschner

AU - Iversen, Lars

N1 - Publisher Copyright: © 2025 The Author(s). Published by S. Karger AG, Basel.

PY - 2025/1

Y1 - 2025/1

N2 - Introduction: Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening form of psoriasis, characterized by widespread sterile pustules and systemic symptoms. While the pathogenesis remains incompletely understood, the interleukin 36 (IL-36) pathway has emerged as a key contributor. Spesolimab, a humanized monoclonal antibody targeting the IL-36 receptor, has shown rapid and marked clinical improvement in patients during acute GPP flares. Case Presentation: We report three cases of GPP flares treated with spesolimab in Denmark, administered prior to its commercial availability through a compassionate use program. All patients presented with severe GPP and were assessed using the Physician's Global Assessment for Generalized Pustular Psoriasis. Treatment with spesolimab resulted in rapid improvement across all cases. Conclusion: These real-world observations support the clinical efficacy of spesolimab for managing acute GPP flares and demonstrate its potential as a therapeutic option in severe cases, even before commercial access.

AB - Introduction: Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening form of psoriasis, characterized by widespread sterile pustules and systemic symptoms. While the pathogenesis remains incompletely understood, the interleukin 36 (IL-36) pathway has emerged as a key contributor. Spesolimab, a humanized monoclonal antibody targeting the IL-36 receptor, has shown rapid and marked clinical improvement in patients during acute GPP flares. Case Presentation: We report three cases of GPP flares treated with spesolimab in Denmark, administered prior to its commercial availability through a compassionate use program. All patients presented with severe GPP and were assessed using the Physician's Global Assessment for Generalized Pustular Psoriasis. Treatment with spesolimab resulted in rapid improvement across all cases. Conclusion: These real-world observations support the clinical efficacy of spesolimab for managing acute GPP flares and demonstrate its potential as a therapeutic option in severe cases, even before commercial access.

KW - Case reports

KW - Compassionate use

KW - Pustular psoriasis

KW - Spesolimab

UR - https://www.scopus.com/pages/publications/105015623629

U2 - 10.1159/000547428

DO - 10.1159/000547428

M3 - Journal article

C2 - 41064317

AN - SCOPUS:105015623629

SN - 1662-6567

VL - 17

SP - 376

EP - 381

JO - Case Reports in Dermatology

JF - Case Reports in Dermatology

IS - 1

ER -